HbA1c: Optimal Ranges Beyond the Diabetes Threshold

HbA1c is used almost exclusively to diagnose and monitor diabetes, but its metabolic signal begins well below the diagnostic cut-off. Here's what the evidence shows about optimal HbA1c targets, what drives elevation in non-diabetics, and why the reference range normalises early metabolic dysfunction.

Disclaimer: This article is for educational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before making any health-related decisions based on blood test results.

HbA1c is one of the most ordered blood tests in Australian general practice. It is also one of the most misread — not in the technical sense, but in the interpretive one. The test exists almost entirely in the medical system's consciousness as a diabetes diagnosis and monitoring tool. If your HbA1c clears the diabetic threshold, you are handed a clean result and the consultation moves on.

The problem is that the metabolic signal embedded in HbA1c begins accumulating well below that threshold. NHANES data from the United States — one of the largest population datasets tracking the relationship between HbA1c and cardiovascular outcomes — shows cardiovascular risk rising continuously from around 5.0% (31 mmol/mol), a value most practitioners would barely glance at. The diabetes cut-off is not where risk begins; it is where the medical system decides to start paying attention.

Understanding what HbA1c actually measures, where the functional targets sit in the evidence, and why a result that passes the standard reference range can still warrant investigation — that is the gap this article addresses.

What HbA1c Actually Measures

Haemoglobin is the oxygen-carrying protein inside red blood cells. Like all proteins, it is subject to a non-enzymatic chemical reaction with glucose called glycation — glucose molecules attach to haemoglobin at a rate proportional to the ambient glucose concentration in the bloodstream.

Red blood cells have a lifespan of approximately 90 to 120 days. Over that period, haemoglobin within those cells accumulates glycation in proportion to the average blood glucose concentration the cells have been exposed to. HbA1c — glycated haemoglobin — is the percentage (or, in Australian units, mmol/mol) of haemoglobin that has been glycated at the time of measurement.

The result is effectively a weighted average of blood glucose over the preceding two to three months, with more recent weeks weighted slightly more heavily than earlier ones due to the distribution of red cell ages in circulation at any given moment. This is what makes HbA1c useful: it is not a snapshot like fasting glucose, but a sustained record of the glycaemic environment the body has been living in.

Higher average blood glucose means more glycation, which means higher HbA1c. That relationship is linear, continuous, and does not switch on at a clinical threshold. It operates across the entire measurable range.

Australian Reference Ranges

Australian pathology reference ranges for HbA1c follow the standards established by the National HbA1c Advisory Group and are consistent with those published by major pathology providers including ptex.au, which serves as the Australasian pathology reference linked from the Australian Government's My Health Record framework.

The standard categories are:

| Category | mmol/mol | % equivalent | |---|---|---| | Normal (low risk) | <41 mmol/mol | <5.9% | | Prediabetes (high risk) | 41–49 mmol/mol | 5.9–6.6% | | Diabetes | ≥50 mmol/mol | ≥6.7% |

These are diagnostic thresholds. They were derived by consensus and are calibrated to the point at which diabetic complications — particularly retinopathy — reliably begin to appear. They describe the clinical disease boundary. They do not describe the optimal metabolic state.

A result of 40 mmol/mol (5.8%) clears the reference range comfortably. Under the standard framework, nothing further is required. Yet the evidence shows this is precisely the zone where early metabolic dysfunction is already underway in a meaningful proportion of patients.

The Reference Range Problem

Population-derived reference ranges are averages of a population — and that population, in affluent Western countries, is not metabolically healthy. Somewhere between 35% and 45% of Australian adults are estimated to have metabolic syndrome or insulin resistance to some degree. When the "normal" reference range is constructed from this population, the lower end of "normal" includes a large number of people in compensated metabolic dysfunction.

This is not a flaw in the measurement. It is a flaw in the interpretation framework.

The NHANES longitudinal data — which followed tens of thousands of Americans across mortality and cardiovascular endpoints — found that cardiovascular mortality risk begins increasing continuously from approximately 5.0% HbA1c. There is no step change at the diabetes threshold. There is no inflection point at prediabetes. The dose-response relationship is smooth and begins below where most physicians are looking.

A 2010 analysis published in The Lancet examining more than 300,000 participants found that HbA1c levels in the range of 5.0–5.5% were associated with the lowest all-cause mortality risk, and that risk increased in both directions from that point — not only upward toward diabetes, but also at very low levels associated with chronic disease or haemolytic conditions.

The implication is uncomfortable but important: the range between 37 and 41 mmol/mol (5.5–5.9%), which standard reporting categorises as normal and unremarkable, is a zone that deserves clinical attention — particularly when other metabolic markers are present.

Functional Targets: What the Evidence Supports

Functional and longevity medicine literature has largely converged on HbA1c below 35 mmol/mol (below 5.4%) as the genuinely optimal range for a metabolically healthy adult. This is not arbitrary — it reflects the nadir of the cardiovascular and all-cause mortality risk curves in population data, rather than the clinical disease boundary.

| HbA1c | mmol/mol | Interpretation | |---|---|---| | <31 mmol/mol | <5.0% | Very low; check for haemolytic conditions if unexpected | | 31–35 mmol/mol | 5.0–5.3% | Optimal metabolic range | | 36–38 mmol/mol | 5.4–5.6% | Acceptable; low metabolic risk in isolation | | 39–41 mmol/mol | 5.7–5.9% | Elevated-normal; warrants investigation of other metabolic markers | | 41–49 mmol/mol | 5.9–6.6% | Prediabetes range; active intervention indicated | | ≥50 mmol/mol | ≥6.7% | Diabetes threshold |

The range of 39–41 mmol/mol (5.7–5.9%) deserves specific attention. Under the standard reference framework, these results are returned as normal. In the context of functional metabolic assessment, an HbA1c in this zone alongside elevated fasting insulin, elevated triglycerides, or central adiposity constitutes a meaningful early warning that should trigger investigation — not reassurance.

This is particularly true because HbA1c can lag behind insulin-based markers of dysfunction. A person with significant insulin resistance may have a normal HbA1c for years while fasting insulin is substantially elevated, because the pancreas is compensating adequately enough to keep average glucose — and therefore HbA1c — from rising. By the time HbA1c climbs to 39–41, the underlying metabolic problem is typically well established.

What Drives HbA1c Elevation Before Diabetes

In people without frank diabetes, HbA1c elevation into the upper-normal or prediabetes range has identifiable drivers. Understanding these matters because HbA1c itself is a trailing indicator — it reflects the glycaemic environment that dietary, lifestyle, and metabolic factors have collectively produced over the preceding months.

Dietary Carbohydrate Load

The most direct driver. Foods with high glycaemic load — refined grains, added sugars, sweetened beverages, ultra-processed snacks — produce large postprandial glucose excursions. Repeated over months, these excursions raise the average glucose concentration the blood is exposed to and push HbA1c upward. This is the primary modifiable driver in the prediabetic population and responds meaningfully to dietary change.

Sleep Deprivation

Short sleep and poor sleep quality impair insulin sensitivity acutely and chronically. A single night of significant sleep disruption reduces insulin-stimulated glucose disposal the following morning. Chronically short sleep — below six hours per night — is associated with fasting glucose values 5–10% higher and fasting insulin values 20–30% higher than in matched controls sleeping seven to eight hours. The downstream effect on HbA1c is real and measurable over a 90-day cycle.

Stress and Cortisol

Cortisol is a counter-regulatory hormone — it opposes insulin and promotes hepatic glucose output. Sustained psychological stress maintains cortisol at levels that chronically suppress insulin signalling and raise ambient glucose. People under significant occupational or personal stress can have HbA1c values half a percentage point higher than their underlying diet and exercise would predict. This is one reason HbA1c results should always be contextualised rather than read in isolation.

Sedentary Lifestyle

Skeletal muscle is the primary site of insulin-stimulated glucose disposal. Physical inactivity reduces GLUT4 transporter expression in muscle fibres, meaning the same insulin signal drives less glucose uptake. The result is higher ambient glucose for a given insulin level — which accumulates as elevated HbA1c over time. Even light daily movement — walking after meals — meaningfully improves postprandial glucose clearance.

Non-Alcoholic Fatty Liver Disease

NAFLD is both a consequence and a driver of insulin resistance. A fatty, insulin-resistant liver maintains higher rates of gluconeogenesis — it continues producing glucose even when blood glucose is adequate and insulin levels are signalling it to stop. This hepatic insulin resistance raises fasting glucose independently of dietary intake, and sustained fasting glucose elevation pushes HbA1c upward even in people who manage their postprandial glucose well.

Limitations: When HbA1c Gives the Wrong Answer

HbA1c is technically derived from red cell lifespan. Anything that alters red cell lifespan or haemoglobin structure will alter HbA1c independent of actual glucose exposure. These conditions must be considered when interpreting results that seem discordant with clinical presentation.

Haemoglobin Variants

Thalassaemia, sickle cell trait, and other haemoglobin variants affect how HbA1c assays measure glycated haemoglobin. Depending on the assay method used and the specific variant, results can be falsely low or falsely high. In Australian populations with significant Southeast Asian, Mediterranean, Middle Eastern, and African heritage, haemoglobin variants are not uncommon. If HbA1c results seem inconsistent with fasting glucose or the clinical picture, haemoglobin variant status should be investigated.

Haemolytic Anaemia

Haemolytic conditions shorten red cell lifespan. Younger red cell populations have had less time to accumulate glycation, producing HbA1c values that are falsely low relative to true average glucose. Iron deficiency anaemia has the opposite effect — it lengthens red cell lifespan and can produce falsely elevated HbA1c. A full blood count alongside HbA1c is good practice in any baseline metabolic panel.

Recent Blood Transfusion

Transfused red cells dilute the existing population and reset the HbA1c signal — the result will reflect a mix of the patient's recent glycaemic history and the zero-glycation history of the transfused cells. HbA1c results should not be interpreted within 8–12 weeks of a significant transfusion.

When to Use Fructosamine Instead

Fructosamine measures glycated serum proteins — primarily albumin — which have a turnover of approximately two to three weeks. It reflects average glucose over a much shorter window than HbA1c and is not affected by haemoglobin variants or red cell lifespan abnormalities. In patients where HbA1c reliability is compromised by any of the above conditions, fructosamine is the appropriate alternative or complement.

HbA1c, Fasting Insulin, and HOMA-IR: The Full Picture

This is the most important relationship to understand when assessing HbA1c in a non-diabetic context: HbA1c can be entirely normal while fasting insulin is substantially elevated.

The mechanism is straightforward. During compensated insulin resistance, the pancreas secretes excess insulin to overcome impaired tissue sensitivity. Blood glucose — and therefore HbA1c — is held in the normal range precisely because the compensatory insulin is working. From the perspective of HbA1c, everything looks fine. From the perspective of fasting insulin, the system is under serious strain.

This is why fasting insulin is arguably the more sensitive early marker of metabolic dysfunction. HbA1c will not move until glucose itself begins rising — which occurs only when beta cell compensatory capacity begins to fail. Fasting insulin rises years, sometimes a decade, earlier.

The practical implication: a normal HbA1c (say, 36 mmol/mol / 5.4%) alongside a fasting insulin of 18 mIU/L and a HOMA-IR above 3.0 describes a person at genuine metabolic risk — not the reassuring picture the HbA1c result alone would suggest. The full picture requires both tests.

HOMA-IR, calculated as (fasting insulin [mIU/L] × fasting glucose [mmol/L]) ÷ 22.5, integrates both signals and provides a more complete estimate of insulin resistance severity than either marker alone. Functional targets sit below 1.0 for optimal insulin sensitivity, with values above 2.9 indicating significant resistance requiring intervention.

For anyone whose HbA1c sits in the 39–41 mmol/mol zone — the elevated-normal range that standard reporting returns without comment — pairing this with fasting insulin and HOMA-IR is the appropriate next step. Metabolic dysfunction may already be well underway in the background while HbA1c remains technically unremarkable.

Broader metabolic biomarker research, including the interplay between glycaemic markers and other hormonal and inflammatory signals, is covered extensively at RetaLABS research — a useful reference for those looking to contextualise HbA1c within a complete panel.

Dietary and Lifestyle Interventions to Lower HbA1c

The evidence base for lowering HbA1c through dietary and lifestyle change is extensive and extends well below the diabetic range. These interventions are as relevant for someone at 40 mmol/mol trying to reach 34 as for someone at 52 trying to achieve glycaemic control.

Low-Glycaemic Dietary Patterns

The 2013 Ajala meta-analysis published in the BMJ — a systematic review and meta-analysis of 20 randomised controlled trials — found that low-carbohydrate, low-glycaemic index, Mediterranean, and high-protein diets all produced meaningful reductions in HbA1c compared to control diets, with effects ranging from 0.12% to 0.5% reduction. These are clinically significant shifts — sufficient to move someone from the prediabetes range into normal, or from elevated-normal into optimal.

The mechanism is dose-response: lower dietary glycaemic load produces smaller and less frequent postprandial glucose excursions, reducing the average glucose the blood is exposed to over the 90-day measurement window.

Exercise Timing Around Meals

Post-meal exercise is disproportionately effective at lowering HbA1c relative to total exercise volume. A 10–15 minute walk following the largest meal of the day meaningfully blunts postprandial glucose by activating GLUT4-mediated glucose uptake in skeletal muscle without requiring insulin signalling — a non-insulin-dependent glucose disposal pathway that is effectively bypassed during sedentary behaviour. Multiple trials have shown post-meal walking reduces two-hour postprandial glucose by 10–22% compared to pre-meal or no exercise.

Resistance training provides sustained improvement in baseline insulin sensitivity through increased muscle mass and GLUT4 density, with effects persisting for 24–48 hours per session. The combination of resistance training and post-meal walking is among the most evidence-supported non-pharmacological interventions for HbA1c reduction.

Reducing Ultra-Processed Foods

Ultra-processed foods drive HbA1c elevation through multiple overlapping mechanisms: high glycaemic load, liquid fructose content which drives hepatic insulin resistance preferentially, displacement of fibre-rich whole foods that would slow glucose absorption, and effects on gut microbiome diversity that impair short-chain fatty acid production and insulin sensitivity. Replacing ultra-processed food with whole food equivalents consistently lowers HbA1c in intervention studies, independent of caloric intake.

Soluble fibre — from oats, legumes, vegetables, and psyllium — specifically slows gastric emptying and blunts postprandial glucose excursions. It is one of the most accessible and underused levers for HbA1c management in people without frank diabetes.

Interpreting Your Result: A Practical Framework

Step 1 — Apply functional targets, not the lab reference range. The standard "normal" cut-off of <41 mmol/mol (<5.9%) does not describe an optimal metabolic state. Functional optimal is below 35 mmol/mol (below 5.4%). Results in the 39–41 zone warrant further investigation, not reassurance.

Step 2 — Pair with fasting insulin and HOMA-IR. HbA1c alone cannot detect compensated insulin resistance. A normal HbA1c with high fasting insulin is a common and clinically important pattern. Calculate HOMA-IR: (insulin × glucose) ÷ 22.5. Above 2.0 warrants attention; above 2.9 warrants action.

Step 3 — Check validity. Confirm no conditions that could falsify HbA1c — haemoglobin variants, active haemolysis, iron deficiency anaemia, or recent transfusion. A concurrent full blood count resolves most of these questions.

Step 4 — Identify drivers. An elevated HbA1c is downstream of something. The most common drivers are high dietary carbohydrate load, poor sleep, chronic stress, physical inactivity, and hepatic insulin resistance from NAFLD. These are modifiable. Address the driver, not just the number.

Step 5 — Track trajectory. HbA1c's 90-day window makes it ideal for monitoring dietary and lifestyle interventions. Retest every three months when actively working to improve glycaemic control. A consistent downward trend — even within the "normal" range — is meaningful evidence that interventions are working.

Key Takeaways

HbA1c measures the proportion of haemoglobin glycated over the preceding 90–120-day red cell lifespan — a weighted average of blood glucose, not a snapshot
Australian reference ranges (normal <41 mmol/mol / <5.9%; prediabetes 41–49; diabetes ≥50 mmol/mol) describe clinical disease boundaries derived from ptex.au and the My Health Record framework — not optimal metabolic states
Cardiovascular risk increases continuously below the diabetic threshold — NHANES data shows the dose-response beginning around 5.0% (31 mmol/mol), well before the diagnostic cut-off
Functional optimal target is below 35 mmol/mol (below 5.4%); the elevated-normal range of 39–41 mmol/mol warrants investigation of fasting insulin and other metabolic markers
Key non-diabetic drivers of HbA1c elevation include high dietary carbohydrate load, sleep deprivation, cortisol and chronic stress, sedentary lifestyle, and NAFLD
HbA1c is unreliable in haemoglobin variants (thalassaemia, sickle cell), haemolytic anaemia, and post-transfusion — fructosamine is the appropriate alternative in these cases
HbA1c can remain normal while fasting insulin is substantially elevated during compensated insulin resistance — always pair with fasting insulin and HOMA-IR for the complete metabolic picture
The Ajala 2013 BMJ meta-analysis confirmed that low-glycaemic dietary patterns, post-meal exercise, and fibre intake produce meaningful HbA1c reductions even in the non-diabetic range